Quantitative Assessment of the Association of COX-2 (Cyclooxygenase-2) Immunoexpression with Prognosis in Human Osteosarcoma: A Meta-Analysis

Wang, Zhe; He, Miao; Xiao, Zengming; Wu, Hao; Wu, Yang

doi:10.1371/journal.pone.0082907

Cited by 11 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peng et al37 found that COX-2 765G>C polymorphism was associated with colorectal cancer risk. Another study by Wang et al38 found that COX-2 overexpression was associated with poor prognosis and cancer progression. COX-2 765G>C is a functional polymorphism located at 765 bp upstream (2,765 bp) from the transcription starting site.…”

Section: Discussionmentioning

confidence: 97%

The prognostic value of cyclooxygenase-2 expression in patients with esophageal cancer: evidence from a meta-analysis

Hu¹,

Yang

Zhao

et al. 2017

OTT

View full text Add to dashboard Cite

Published studies have investigated the prognostic role of cyclooxygenase-2 (COX-2) expression in patients with esophageal cancer (EC), but the result remains controversial. Thus, this meta-analysis was conducted to comprehensively evaluate the impact of COX-2 expression on the prognostic value in patients with EC. Relevant studies were identified from PubMed, EMBASE, and Web of Science databases. Studies that detected the COX-2 expression by immunohistochemistry and evaluated the relationship between COX-2 expression and overall survival (OS) or clinicopathological parameters were used in our analysis. The summary hazard ratios (HRs) or odds ratios were calculated to assess the risk or hazard association. A total of 25 studies, which included 2,465 patients, were included in our meta-analysis. Our analysis suggested that overexpression of COX-2 was associated with poor OS (HR =1.60, 95% CI =1.32–1.94, P<0.001). Subgroup analyses by race, percentage of high/positive COX-2 expression, histology type, treatment, and sample size all suggested significant association. Moreover, overexpression of COX-2 was significantly associated with depth of invasion, lymph node metastasis, distant metastasis, and TNM stage. This meta-analysis suggested that overexpression of COX-2 might serve as a prognostic biomarker for EC. Large well-designed prospective studies are needed to confirm our conclusion.

show abstract

Section: Discussionmentioning

confidence: 97%

The prognostic value of cyclooxygenase-2 expression in patients with esophageal cancer: evidence from a meta-analysis

Hu¹,

Yang

Zhao

et al. 2017

OTT

View full text Add to dashboard Cite

show abstract

“…COX-2 expression has been found to be associated with an increased risk of tumor recurrence, advanced cancer stage and/ or poor overall survival in a large number of cancers such as ovarian cancer [28,29], osteosarcoma [30,31], pancreatic cancer [32], gastric cancer [33][34][35], classical Hodgkin's lymphoma [36], oral squamous cell cancer [37], melanoma [38], non-small cell lung cancer [39] but not lung adenocarcinoma [40], clear cell renal carcinoma [41], cervical cancer [42] and esophageal adenocarcinoma [43]. The specific expression of COX-2 in breast and colon cancers is detailed later in this article.…”

Section: Cox-2 Expression In Cancermentioning

confidence: 99%

New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis

Hugo

Saunders

Ramsay

et al. 2015

J Mammary Gland Biol Neoplasia

View full text Add to dashboard Cite

The medicinal use of aspirin stretches back to ancient times, before it was manufactured in its pure form in the late 19th century. Its accepted mechanistic target, cyclooxygenase (COX), was discovered in the 1970s and since this landmark discovery, the therapeutic application of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has increased dramatically. The most significant benefits of NSAIDs are in conditions involving chronic inflammation (CI). Given the recognized role of CI in cancer development, the use of long-term NSAID treatment in the prevention of cancer is an enticing possibility. COX-2 is a key driver of CI, and here we review COX-2 expression as a predictor of survival in various cancer types, including breast. Obesity and post-partum involution are natural inflammatory states that are associated with increased breast cancer risk. We outline the COX-2 mediated mechanisms contributing to the growth of cancers. We dissect the cellular mechanism of epithelial-mesenchymal transition (EMT) and how COX-2 may induce this to facilitate tumor progression. Finally we examine the potential regulation of COX-2 by c-Myb, and the possible interplay between c-Myb/COX-2 in proliferation, and hypoxia inducible factor-1 alpha (HIF1α)/COX-2 in invasive pathways in breast cancer.

show abstract

“…COX-2 was also found overexpressed frequently in osteosarcoma, which promoted malignant potential of neoplasms [ 20 , 21 ] and was associated with poor prognosis for patients with osteosarcoma [ 22 , 23 ]. Celecoxib, a selective COX-2 inhibitor, can induce osteosarcoma cell apoptosis via inhibiting COX-2 [ 24 , 25 ], and has been applied for the clinical trials to treat osteosarcoma and Ewing sarcoma [ 26 , 27 ].…”

Section: Introductionmentioning

confidence: 99%

ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib

Liu

Zhou

et al. 2015

Oncotarget

View full text Add to dashboard Cite

ZD6474, a small molecule VEGFR and EGFR tyrosine kinase inhibitor, has been considered as a promising tumor-targeted drug in various malignancies. EGFR and cyclooxygenase-2 (COX-2) were found overexpressed in osteosarcoma in previous reports, so here we tried to explore the anti-osteosarcoma effect of ZD6474 alone or combination with celecoxib, a COX-2 inhibitor. The data demonstrated that ZD6474 inhibited the growth of osteosarcoma cells, and promoted G1-phase cell cycle arrest and apoptosis by inhibiting the activity of EGFR tyrosine kinase, and consequently suppressing its downstream PI3k/Akt and MAPK/ERK pathway. Additionally, daily administration of ZD6474 produced a dose-dependent inhibition of tumor growth in nude mice. Celecoxib also significantly inhibited the growth of osteosarcoma cells in dose-dependent manner, while combination of ZD6474 and celecoxib displayed a synergistic or additive antitumor effect on osteosarcoma in vitro and in vivo. The possible molecular mechanisms to address the synergism are likely that ZD6474 induces the down-regulation of COX-2 expression through inhibiting ERK phosphorylation, while celecoxib promotes ZD6474-directed inhibition of ERK phosphorylation. In conclusion, ZD6474 exerts direct anti-proliferative effects on osteosarcoma cells, and the synergistic antitumor effect of the combination of ZD6474 with celecoxib may indicate a new strategy of the combinative treatment of human osteosarcoma.

show abstract

Quantitative Assessment of the Association of COX-2 (Cyclooxygenase-2) Immunoexpression with Prognosis in Human Osteosarcoma: A Meta-Analysis

Cited by 11 publications

References 31 publications

The prognostic value of cyclooxygenase-2 expression in patients with esophageal cancer: evidence from a meta-analysis

The prognostic value of cyclooxygenase-2 expression in patients with esophageal cancer: evidence from a meta-analysis

New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis

ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib

Contact Info

Product

Resources

About